What is Egalet?
Headquartered in Wayne, Egalet Corporation operates at the intersection of pharmaceutical innovation and patient safety. The company specializes in the development, manufacturing, and commercialization of treatments for pain and related conditions, with a distinct focus on abuse-deterrent formulations. Its market position is anchored by a portfolio that includes SPRIX Nasal Spray, OXAYDO, and ARYMO ER. These products address critical needs in the analgesic market by providing effective pain management while mitigating the risks associated with opioid misuse. Through strategic collaborations with partners like Acura Pharmaceuticals and Septodont, Egalet has effectively extended its reach, ensuring its specialized therapies reach adult patients requiring rigorous pain management protocols.
How much funding has Egalet raised?
Egalet has raised a total of $207.5M across 6 funding rounds:
Share Placement
$13.3M
Series B
$33.6M
Unspecified
$20M
Stock Offering
$58.4M
Debt
$40M
Unspecified
$42.2M
Share Placement (2001): $13.3M with participation from Bio Fund, Danske Bank, Dask Kapitalanlaeg, and QueQuoin Holdings
Series B (2012): $33.6M led by QueQuoin Holdings, Atlas Ventures, Dansk Kapitalanlaeg, Danske Bank, Index Ventures, Bio Fund, Sunstone Capital, Omega Funds, Vaekstfonden Life Science Ventures, and CLS Capital
Unspecified (2013): $20M supported by Index Ventures
Stock Issuance/Offering (2014): $58.4M featuring Undisclosed
Debt (2016): $40M backed by Morgan Stanley & Co.
Unspecified (2019): $42.2M with participation from Undisclosed
Key Investors in Egalet
Morgan Stanley & Co.
A leading global financial services firm providing a wide range of investment banking, securities, wealth management, and investment management services to corporations and institutions worldwide.
Atlas Venture
A pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
Index Ventures
A venture firm investing in the next generation of entrepreneurs from seed to IPO, partnering with founders who challenge the status quo to build enduring companies.
What's next for Egalet?
Looking ahead, Egalet is positioned to leverage its recent capital infusion to accelerate the development of its pipeline, most notably the Phase III clinical trials for Egalet-002. The strategic focus remains on scaling the commercial footprint of its existing abuse-deterrent products while navigating the regulatory landscape for its next-generation stimulant and hydrocodone-based candidates. As the company matures, the integration of its Guardian Technology across a broader therapeutic range will be pivotal in maintaining its competitive edge. Investors are closely monitoring the firm's ability to convert its clinical progress into sustained revenue growth, as the company continues to refine its operational efficiency and market penetration strategies in the highly regulated pharmaceutical sector.
See full Egalet company page
